The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Could RO7851624, newly into clinical trials, be RG6735?
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
No sooner does one gammadelta-focused biotech die than another takes its place.
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
